HUMA vs. HRMY, MIRM, BEAM, CNTA, MESO, IDYA, AGIO, APGE, TARS, and IOVA
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Harmony Biosciences (HRMY), Mirum Pharmaceuticals (MIRM), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Mesoblast (MESO), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Tarsus Pharmaceuticals (TARS), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs.
Harmony Biosciences (NASDAQ:HRMY) and Humacyte (NASDAQ:HUMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Harmony Biosciences has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
In the previous week, Humacyte had 9 more articles in the media than Harmony Biosciences. MarketBeat recorded 27 mentions for Humacyte and 18 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.86 beat Humacyte's score of 0.25 indicating that Harmony Biosciences is being referred to more favorably in the media.
Harmony Biosciences has a net margin of 17.98% compared to Humacyte's net margin of 0.00%. Harmony Biosciences' return on equity of 23.16% beat Humacyte's return on equity.
Harmony Biosciences received 22 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 67.47% of users gave Harmony Biosciences an outperform vote while only 66.67% of users gave Humacyte an outperform vote.
86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 30.8% of Harmony Biosciences shares are owned by company insiders. Comparatively, 11.2% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Harmony Biosciences has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
Harmony Biosciences presently has a consensus price target of $55.00, indicating a potential upside of 40.85%. Humacyte has a consensus price target of $13.71, indicating a potential upside of 210.98%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Harmony Biosciences.
Summary
Harmony Biosciences beats Humacyte on 13 of the 18 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free HUMA Stock Alerts